Antidepressants Market Size, Share, Growth | Forecast 2031

Segments - Antidepressants Market by Products (Selective Serotonin Reuptake Inhibitor [SSRI], Serotonin-norepinephrine Reuptake Inhibitor [SNRI], Tricyclic Antidepressant [TCA], Monoamine Oxidase Inhibitor [MAOI], and Other Products), Depressive Disorders (Major Depressive Disorder, Obsessive-compulsive Disorder [OCD], Generalized Anxiety Disorder [GAD], Panic Disorder [PD], and Other Depressive Disorders), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Antidepressants Market Outlook 2031:

The global antidepressants market size was valued at USD 12.72 Billion in 2022 and is projected to reach USD 16.45 Billion by 2031, expanding at a CAGR of 2.9% during the forecast period 2023 - 2031. The growth of the market is attributed to the rising mental problems among the general public.

Depression refers to a group of mental health issues marked by a lack of positive feeling, a depressed mood, and a variety of cognitive, physical, emotional, and behavioral symptoms. It's a highly prevalent ailment that affects one out of every five Americans. Depression can be caused by a variety of causes, including genetics, stress, and brain chemistry.

Depression is caused mostly by variables such as social isolation and a stressful work environment, which have contributed significantly to the rise in the number of persons suffering from depression. According to the World Health Organization, depression afflicted almost 350 million people globally in 2016. Antidepressants aid in the treatment of depression by maintaining the balance of different hormones and chemicals in the brain.

Given the challenges experienced during the crisis, such as social isolation due to lockdown, employment uncertainty, and fear of getting infected by coronavirus, the pandemic is expected to have a long- and short-term influence on the individual's mental disorder. According to a survey conducted by the Kaiser Family Foundation in August 2020, 64 per cent of households with a healthcare worker reported having experienced at least one negative effect on their mental health and wellbeing during the COVID-19 pandemic, such as difficulty sleeping or eating, increased alcohol consumption or substance use, and worsening chronic conditions.

Antidepressants Market Trends, Drivers, Restraints, and Opportunities

Growing awareness of depression among people is expected to drive the antidepressants market growth during the forecast period.
Introduction of new biologics is anticipated to fuel the antidepressants market expansion in the coming years.
Rising geriatric population and mental health associated risks are estimated to spur market growth in the coming years.
Availability of non-drug therapies and anti-depressant side effects are expected to limit the antidepressants market growth throughout the projection period.
Increase in the number of antidepressant patent expirations is projected to impede market expansion.

Scope of Antidepressants Market Report

The report on the global antidepressants market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Antidepressants Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016 – 2021
Forecast Period	2023 – 2031
Segmentation	Products (Selective Serotonin Reuptake Inhibitor [SSRI], Serotonin-norepinephrine Reuptake Inhibitor [SNRI], Tricyclic Antidepressant [TCA], Monoamine Oxidase Inhibitor [MAOI], and Other Products) and Depressive Disorders (Major Depressive Disorder, Obsessive-compulsive Disorder [OCD], Generalized Anxiety Disorder [GAD], Panic Disorder [PD], and Other Depressive Disorders)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, and Pfizer Inc.

Antidepressants Market Segment Insights

Selective serotonin reuptake inhibitor [SSRI] segment is projected to account for a large market share

Based on products, the antidepressants market share is bifurcated into selective serotonin reuptake inhibitor [SSRI], serotonin-norepinephrine reuptake inhibitor [SNRI], tricyclic antidepressant [TCA], monoamine oxidase inhibitor [MAOI], and other products.

The selective serotonin reuptake inhibitor [SSRI] segment is expected to account for a key share of the market during the forecast period owing to the availability of these medications in huge amounts.

Major depressive disorder segment is expected to grow at a rapid pace

In terms of depressive disorders, the antidepressants market is divided into major depressive disorder, obsessive-compulsive disorder [OCD], generalized anxiety disorder [GAD], panic disorder [PD], and other depressive disorders.

The major depressive disorder segment is expected to account for a key share of the market in the coming years due to the growing patient pool and new product releases.

Antidepressants Market Depressive Disorders

North America is anticipated to dominate the market

On the basis of regions, the antidepressants market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to the rising prevalence of depression.

Furthermore, the geriatric population in the United States is growing, which would provide additional possibilities for market participants in the area. Furthermore, the studied market is driven by an increase in FDA approvals and pipeline goods by significant companies located in the area. For example, the US FDA authorized Spravato (esketamine) nasal spray in March 2019 for the treatment of resistant depression in adults when used in combination with an oral antidepressant.

Segments

The global antidepressants market has been segmented on the basis of

Products

Selective Serotonin Reuptake Inhibitor [SSRI]
Serotonin-norepinephrine Reuptake Inhibitor [SNRI]
Tricyclic Antidepressant [TCA]
Monoamine Oxidase Inhibitor [MAOI]
Other Products

Depressive Disorders

Major Depressive Disorder
Obsessive-compulsive Disorder [OCD]
Generalized Anxiety Disorder [GAD]
Panic Disorder [PD]
Other Depressive Disorders

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Allergan PLC
AstraZeneca
Eli Lilly and Company
GlaxoSmithKline PLC
H. Lundbeck AS
Johnson & Johnson
Pfizer Inc.

Competitive Landscape

Key players competing in the global antidepressants market include Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, and Pfizer Inc.
Antidepressants Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antidepressants Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Antidepressants Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Antidepressants Market - Supply Chain
  4.5. Global Antidepressants Market Forecast
     4.5.1. Antidepressants Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Antidepressants Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Antidepressants Market Absolute $ Opportunity
5. Global Antidepressants Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Antidepressants Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Antidepressants Demand Share Forecast, 2019-2026
6. North America Antidepressants Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Antidepressants Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Antidepressants Demand Share Forecast, 2019-2026
7. Latin America Antidepressants Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Antidepressants Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Antidepressants Demand Share Forecast, 2019-2026
8. Europe Antidepressants Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Antidepressants Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Antidepressants Demand Share Forecast, 2019-2026
9. Asia Pacific Antidepressants Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Antidepressants Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Antidepressants Demand Share Forecast, 2019-2026
10. Middle East & Africa Antidepressants Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Antidepressants Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Antidepressants Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Antidepressants Market: Market Share Analysis
  11.2. Antidepressants Distributors and Customers
  11.3. Antidepressants Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Allergan PLC
     11.4.2. AstraZeneca
     11.4.3. Eli Lilly and Company
     11.4.4. GlaxoSmithKline PLC
     11.4.5. H. Lundbeck AS
     11.4.6. Johnson & Johnson